XClose

UCL Department of Biochemical Engineering

Menu

The Hub Users

The Hub will address the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.

The Future Targeted Healthcare Manufacturing Hub is supported by over 40 partnering companies and organisations with interests in the sector, to revolutionise the delivery of cost-effective stratified protein-based and personalised cell-based therapies to patients. Representatives are invited to meet twice a year as the Hub User Steering Committee (USC) to provide advice and guidance on the overall direction and progress of the Hub research programme.

In addition, there are 5 Specialist Working Groups (SWGs) for members to engage around key research themes in more detail and provide technical-level advice and steer:

  • Digital Decisional Tools
  • Cell-free Synthesis
  • ATMP Manufacturing
  • Formulation
  • Regulatory Strategies, Reimbursement and Policy

Hub User Steering Committee Members*:

Companies: 3M, Adaptimmune Therapeutics, Aglaris, Albumedix, Applikon Biotechnology, AstraZeneca, Autolus, BIA Separations (Sartorius), Biologic B, BioPharm Services, CSL, deltaDOT, Eli Lilly, Fujifilm Diosynth Biotechnologies, GSK, Ipsen, Kymab, Kuopio Centre for Cell and Gene Therapy, Lonza, Orchard Therapeutics, Oxford BioMedica, Pall, Perceptive, Pharmaron, Puridify (Cytiva), Purolite, ReNeuron, Repligen, Sartorius, SSC Bio, Sutro BioPharma, Tillingbourne Consulting, TrakCel, Univercells, West Pharmaceutical Services, Wyatt Technology

Industry/Govt Associations/Charities: ABPI, BIA, Cancer Research UK, KTN, LGC, MMIP, NIBSC

Translational Spokes: Cell and Gene Therapy Catapult, Centre for Process Innovation/NBMC  

* Signatories of the Collaboration agreement at April 2021

image of hub partner logos as of October 2021

Research Excellence

  • Access to internationally-leading academics and top research graduates with expertise in bioprocessing, decisional tools, process control and analytics, cell therapy manufacture.
  • Wider collaboration opportunities within the Hub User Group via Engineering Doctorate (EngD) studentships.
  • Opportunity to create a Centre of Excellence with UCL focusing on a series of linked research projects for a more holistic and synergistic approach.

Influence in the Sector

  • Steer the research agenda over the next 7 years, aligned to your organisation’s priorities.
  • Participate in user feasibility projects to evaluate Hub outputs using your systems and processes.
  • Boost your profile through joint peer-reviewed articles from user feasibility projects.
  • Leverage funding for greater impact via industry-led InnovateUK projects.

Priority Access to Hub Outputs

  • Early access to new process, analysis and control technologies and methodologies via the Collaboration Agreement and IP provisions.
  • Benefit from novel decision-support tools providing a robust framework for selecting development and manufacturing options, thus reducing the risk of misallocating significant cost and time.
  • Access to highly skilled graduating doctoral and PDRA researchers.